image: This is the journal cover image. view more
Credit: Future Science Group
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology. The journal features articles written by members of its editorial board focused on developing treatments and issues in cardiac care for women, blood pressure targets, and the evolution of genetics and drug response. Future Cardiology is published bimonthly by Future Science Group.
"We launched this journal in recognition of both the rapid rate of advancement in our field and the growing patient population, and we are pleased to offer a review of three critical areas of development in cardiac research and treatment," said Ellen Clarke, Commissioning Editor. "We are always delighted to include the work of the researchers that make up our editorial board; their hard work over the years has been a great assistance in maintaining the journal's high standards at a time when advancement in our field is exceptional."
The three featured articles include "Blood Pressure Target Goals From Guidelines of 2002 to 2014," by Wilbert S. Aronow, MD; "Evolving Cardiovascular Care for Women: A Decade of Progress," by Nanette K. Wenger, MD; and "Pharmacogenomics in Cardiology - Genetics and Drug Response: 10 Years of Progress," by Larisa H. Cavallari, MD.
Dr. Aronow reviews hypertension guidelines from 2002 to 2014, specifically focusing on differing recommendations on whether or not to reduce systolic blood pressure for older patients. "I agree with the 2014 Joint National Committee minority report recommending that these older persons should have their systolic blood pressure reduced to less than 140 mm Hg to reduce cardiovascular events," said Dr. Aronow. "The recently published 2015 American Heart Association/American College of Cardiology/American Society of Hypertension scientific statement on treatment of hypertension in patients with coronary artery disease also recommends reducing the systolic blood pressure to less than 140 mm Hg in these older persons."
###
Future Cardiology is published bi-monthly and highlights the new molecular approach to advancing cardiovascular therapy. Coverage also reflects the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
View the 10- year anniversary special issue - http://www.futuremedicine.com/toc/fca/11/3
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites includes Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com/
Journal
Future Cardiology